Carla Indennidate

Amyloidosis

Valentina Allegro, Carla Indennidate, Andrea Lalario, Aldostefano Porcari et autres

it (code pays fourni par la source)

Device-pocket fat sampling for amyloid screening during cardiac device implantation: a prospective study

Teresa Maria Capovilla, Rossana Bussani, Marco Pozzan, Carla Indennidate et autres

Teresa Maria Capovilla, MD, Rossana Bussani, MD, Marco Pozzan, MD, Carla Indennidate, MD, Eugenia Dal Bo, Cosimo Carriere, MD, Massimo Zecchin, MD, Marco M

nl, it (code pays fourni par la source)

Polygenic risk in early-onset coronary artery disease with low prevalence of traditional cardiovascular risk factors

Maddalena Rossi, Andrea Conti, Giulia Gagno, Stefania Cappellani et autres

AIMS: We aimed to investigate the potential role of polygenic risk in early-onset coronary artery disease (CAD) and recurrence of major adverse coronary events (MACE) in patients with low prevalence of traditional cardiovascular risk factors (CVRFs). METHODS: This was a prospective study …

nl, it (code pays fourni par la source)

Cardiorenal and Metabolic Dimensions of Cardiomyopathies and Heart Failure: Focus on SGLT2i, GLP1-RA, and ns-MRA

Carla Indennidate, Brigitta Perencin, Vittorio Di Maso, Iris Buda et autres

it (code pays fourni par la source)

Case report: recurrent chest pain as initial manifestation of rapidly progressing light-chain cardiac amyloidosis with microvascular infiltration—a novel red flag associated with poor outcomes

Carla Indennidate, Aldostefano Porcari, Rossana Bussani, Marco Merlo et autres

Background: Angina due to microvascular amyloid infiltration is an under-recognized early red flag of infiltrative disease and should be investigated as a predictor of poor outcomes. Case summary: A 73-year-old man with cardiovascular risk factors and a history of treated obstructive coronary …

it, nl, gb, us (code pays fourni par la source)

Leveraging Large-Scale ECG Representations for Interpretable Detection of Cardiac Amyloidosis in a Clinical Cohort

Ilaria Gandin, Carla Indennidate, Riccardo Treu, Aldostefano Porcari et autres

INTRODUCTION Deep neural networks (DNNs) have shown strong performance in diagnostic classification of raw electrocardiogram (ECG) signals. However, their clinical utility remains limited due to the scarcity of large annotated datasets and the inherent lack of interpretability. Variational autoencoders (VAEs), a class …

it (code pays fourni par la source)

Cardiac scintigraphy for transthyretin amyloidosis: a decade of progress, a future of precision

Carla Indennidate, Gianfranco Sinagra, Marco Merlo

TTR amyloidosis

it, nl (code pays fourni par la source)

The PREVASC study: Prospective REgistry of Valve disease in Asymptomatic Italian elderly SubjeCts

Nazario Carrabba, Mattia Alexis Amico, Matteo Vannini, Filippo Bruscoli et autres

AIMS: Valvular heart disease (VHD) is the third leading cause of cardiovascular morbidity, with its incidence and public health impact projected to increase significantly. This study adopts a novel perspective, focusing on elderly individuals residing in rural areas, highlighting the unique dynamics …

it (code pays fourni par la source)

Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records

Giulia Barbati, Caterina Gregorio, Arjuna Scagnetto, Carla Indennidate et autres

Low-Density Lipoprotein (LDL) cholesterol is one of the main target for cardiovascular (CV) prevention and therapy. In the last years, Proprotein Convertase Subtilisin-Kexin type 9 inhibitors (PCSK9-i) has emerged as a key therapeutic target to lower LDL and were introduced for prevention …

it, se (code pays fourni par la source)

Amyloidosis and Amyloidogenesis

Marco Pozzan, Carla Indennidate, Guerino Giuseppe Varrà, Gianfranco Sinagra et autres

it, nl (code pays fourni par la source)

Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors

Caterina Gregorio, Federico Rea, Francesca Ieva, Arjuna Scagnetto et autres

OBJECTIVES: This study aims to show the application of flexible statistical methods in real-world cost-effectiveness analyses applied in the cardiovascular field, focusing specifically on the use of proprotein convertase subtilisin-kexin type 9 inhibitors for hyperlipidemia. METHODS: The proposed method allowed us to …

it, se (code pays fourni par la source)

Lo scompenso cardiaco negli ultimi anni: nuove frontiere

Gianfranco Sinagra, Maddalena Rossi, Carla Indennidate, Marco Cittar et autres

Negli ultimi dieci anni il numero di terapie farmacologiche per il trattamento dell’insufficienza cardiaca con frazione di eiezione ridotta è quasi raddoppiato. Inoltre, e per la prima volta, una nuova classe di farmaci ha dimostrato di migliorare la prognosi in pazienti con …